BioMarin's Novel Treatment Promises to Disrupt Competitors
Gene therapy maker BioMarin Pharmaceuticals (NASDAQ: BMRN) has seen impressive growth recently, with the stock up more than 46% since October.
The 22-year-old company focuses on developing innovative therapies for rare genetic diseases, addressing conditions such as hemophilia, phenylketonuria (PKU), and a few others affecting children.
Most recently, BioMarin has been working on a novel therapy that promises to give its competitors, such as Roche (OTC: RHHBY) and Sangamo Therapeutics (NASDAQ: SGMO), a run for their money in this space. A recent update on BioMarin's manufacturing plans indicates that the company plans to leave no room for its competitors to grow.
Source Fool.com
